论文部分内容阅读
Veliparib是雅培生命研发的一种口服的PARP抑制剂。Veliparib正在开展用于晚期鳞状非小细胞肺癌治疗的研究。正在研究将Veliparib与DNA损伤疗法联用后是否可以阻碍Veliparib损伤修复机制进而促进肿瘤细胞死亡。(源自:药品资讯网)
Veliparib is an oral PARP inhibitor developed by Abbott Life. Veliparib is conducting research for the treatment of advanced squamous non-small cell lung cancer. It is studying whether the combination of Veliparib and DNA damage therapy can block the Veliparib injury repair mechanism and thus promote tumor cell death. (From: Drug Information Network)